Delivery Order SPE2DB22D1202-SPE2DB25FVHF4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,048.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit-dose tablets) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with performance occurring at its corporate office location in the same city....
- The Defense Logistics Agency awarded a delivery order valued at $4,338.57 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging, quantities of 16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and was competitively awarded without set-aside designation. The pharmaceutical will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $4,510.59 to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (10-tablet strips). This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 11, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which runs...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $22,277.22 by the Defense Logistics Agency for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10s. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 31, 2025. The award was executed on July 30, 2025, and represents a child contract under AmerisourceBergen's larger relationship with DLA as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (Ubrogepant) 100 mg tablets, unit dose packages of 10, valued at $1,158.25 with a firm fixed price structure. This award, issued on July 21, 2025, represents a non-set-aside competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the contractor's distribution facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of UBRELVY 50 mg tablets (10-count unit dose packaging) with a ceiling value of $4,919.80 and an ultimate completion date of August 4, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,201.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose packs) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract is being performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets in unit dose packages of 10, valued at $1,595.01. This competitively awarded, firm fixed-price delivery order was issued on July 24, 2025, with an ultimate completion date of July 25, 2025. The contract involves no set-aside designation and identifies AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania as the place of performance. This delivery order...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVHF4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 16 units, valued at $6,817.39. This contract, executed on August 13, 2025, with completion targeted for August 14, 2025, represents a firm fixed-price delivery order with no set-aside designation. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026 that serves as the primary global pharmaceutical support mechanism for military healthcare operations. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a significant role in federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's contract portfolio demonstrates extensive capabilities in supplying specialty medications, brand-name and generic pharmaceuticals, vaccines, and specialized medical supplies across multiple therapeutic domains. This delivery order for UBRELVY, a migraine treatment medication, exemplifies the routine pharmaceutical resupply operations conducted under the broader pharmaceutical prime vendor framework, which DLA is evolving through its planned Pharmaceutical Prime Vendor Global Program Generation V initiative.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.8k | 8/13/25 |